R A Marr
Overview
Explore the profile of R A Marr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
158
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hafez D, Huang J, Richardson J, Masliah E, Peterson D, Marr R
Neuroscience
. 2012 Aug;
223:465-72.
PMID: 22863679
Alzheimer's disease (AD) is the most prevalent form of dementia affecting the elderly. Evidence has emerged signifying that stimulation of the reelin pathway should promote neural plasticity and suppress molecular...
2.
Marr R, Spencer B
Curr Alzheimer Res
. 2010 Jan;
7(3):223-9.
PMID: 20088804
The accumulation of the amyloid-beta peptide (Abeta) continues to emerge as a central factor in Alzheimer's disease (AD). In recent years attention has been drawn to clearance mechanisms of Abeta...
3.
Huang J, Bruno A, Patel C, Huynh A, Philibert K, Glucksman M, et al.
Neuroscience
. 2008 Jun;
155(1):258-62.
PMID: 18571334
Beta-amyloid (Abeta) degrading endopeptidases are thought to protect against Alzheimer's disease (AD) and are potentially therapeutic. Of particular interest are endopeptidases that are blocked by thiorphan and phosphoramidon (T/P), as...
4.
Marr R, Hitt M, Gauldie J, Muller W, Graham F
Cancer Gene Ther
. 1999 Oct;
6(5):465-74.
PMID: 10505857
The toxic effects of tumor necrosis factor alpha (TNFalpha) have greatly limited its use in tumor therapy. Recently, clear evidence has been obtained linking the p55 TNF receptor (TNFR) to...
5.
Sime P, Marr R, Gauldie D, Xing Z, Hewlett B, Graham F, et al.
Am J Pathol
. 1998 Sep;
153(3):825-32.
PMID: 9736031
Tumor necrosis factor-alpha is up-regulated in a variety of different human immune-inflammatory and fibrotic pulmonary pathologies. However, its precise role in these pathologies and, in particular, the mechanism(s) by which...
6.
Lei X, Ohkawara Y, Stampfli M, Mastruzzo C, Marr R, Snider D, et al.
J Clin Invest
. 1998 Apr;
101(6):1342-53.
PMID: 9502776
The objective of this study was to investigate the contribution of the interaction between CD40 and its ligand (CD40L) to antigen-induced airways inflammatory responses. To this end, we used a...
7.
Marr R, Hitt M, Muller W, Gauldie J, Graham F
Int J Oncol
. 1998 Apr;
12(3):509-15.
PMID: 9472086
Induction of systemic toxicity is a major factor limiting the use of TNFa in tumour therapy. The local expression of TNFa from Ad vector infected tumour cells, might result in...
8.
Marr R, Addison C, Snider D, Muller W, Gauldie J, Graham F
Gene Ther
. 1998 Jan;
4(11):1181-8.
PMID: 9425441
The most limiting factor regarding the use of TNF alpha in tumour therapy is systemic toxicity. The expression of membrane-bound (nonsecreted) TNF alpha within a tumour may serve to reduce...